Proactive Investors - Run By Investors For Investors

Bioxytran Inc in advanced talks to take its two exciting assets into the clinic

David Platt, chief executive of Bioxytran Inc (OTCMKTS:BIXT), chats to Proactive Investors at the Spring Investor Summit 2019 in New York City.

The company's mission is to develop anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia.

Its lead candidate BXT-25 is a drug that carries oxygen to tissues when the flow of blood is blocked.

 
View full PROAC profile View Profile

Proactiveinvestors Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use